Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Theravance Biopharma (TBPH) over the last 12 years, with Q3 2025 value amounting to $3.7 million.

  • Theravance Biopharma's Treasury Shares fell 1273.02% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year decrease of 1273.02%. This contributed to the annual value of $4.0 million for FY2024, which is 100.76% down from last year.
  • Latest data reveals that Theravance Biopharma reported Treasury Shares of $3.7 million as of Q3 2025, which was down 1273.02% from $4.1 million recorded in Q2 2025.
  • Theravance Biopharma's 5-year Treasury Shares high stood at $15.6 million for Q3 2023, and its period low was $3.1 million during Q1 2024.
  • For the 5-year period, Theravance Biopharma's Treasury Shares averaged around $6.2 million, with its median value being $4.4 million (2024).
  • As far as peak fluctuations go, Theravance Biopharma's Treasury Shares skyrocketed by 6728.05% in 2021, and later tumbled by 7258.68% in 2024.
  • Over the past 5 years, Theravance Biopharma's Treasury Shares (Quarter) stood at $8.4 million in 2021, then crashed by 50.8% to $4.1 million in 2022, then fell by 2.78% to $4.0 million in 2023, then dropped by 1.01% to $4.0 million in 2024, then fell by 5.53% to $3.7 million in 2025.
  • Its last three reported values are $3.7 million in Q3 2025, $4.1 million for Q2 2025, and $4.5 million during Q1 2025.